{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:03:59Z","timestamp":1776182639588,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"7_Supplement_3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,1]]},"DOI":"10.2146\/ajhp100078","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T21:02:32Z","timestamp":1269378152000},"page":"S20-S30","source":"Crossref","is-referenced-by-count":29,"title":["Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer"],"prefix":"10.1093","volume":"67","author":[{"given":"Laura Boehnke","family":"Michaud","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Services, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104110902300_b1-0670s20","unstructured":"American Cancer Society. Cancer facts and figures 2009. Atlanta, GA: American Cancer Society; 2009. www.cancer.org\/downloads\/STT\/500809web.pdf (accessed 2009 Nov 24)."},{"key":"key\n\t\t\t\t2019041104110902300_b2-0670s20","unstructured":"American Cancer Society. Cancer statistics 2009 presentation. www.cancer.org\/docroot\/PRO\/content\/PRO_1_1_Cancer_Statistics_2009_Presentation.asp (accessed 2009 Dec 3)."},{"key":"key\n\t\t\t\t2019041104110902300_b3-0670s20","unstructured":"American Cancer Society. Breast cancer facts & figures 2009\u20132010. Atlanta, GA: American Cancer Society; 2009. www.cancer.org\/downloads\/STT\/F861009_final%209-08-09.pdf (accessed 2009 Dec 3)."},{"key":"key\n\t\t\t\t2019041104110902300_b4-0670s20","unstructured":"National Osteoporosis Foundation. Clinician\u2019s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008. www.nof.org\/professionals\/Clinicians_Guide.htm (accessed 2009 Nov 24)."},{"issue":"(11 Suppl 1)","key":"key\n\t\t\t\t2019041104110902300_b5-0670s20","doi-asserted-by":"crossref","first-page":"3785S","DOI":"10.1093\/jn\/133.11.3785S","article-title":"Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors","volume":"133","author":"Rock","year":"2003","journal-title":"J Nutr."},{"key":"key\n\t\t\t\t2019041104110902300_b6-0670s20","first-page":"1235","article-title":"Tamoxifen citrate","volume-title":"AHFS drug information 2009","author":"McEvoy","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b7-0670s20","volume-title":"Fareston package insert","year":"2004"},{"key":"key\n\t\t\t\t2019041104110902300_b8-0670s20","volume-title":"Evista package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104110902300_b9-0670s20","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1200\/JCO.2008.19.6162","article-title":"High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy","volume":"27","author":"Crew","year":"2009","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b10-0670s20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/07853899708999335","article-title":"The thyroid and breast cancer: a significant association?","volume":"29","author":"Smyth","year":"1997","journal-title":"Ann Med."},{"key":"key\n\t\t\t\t2019041104110902300_b11-0670s20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/bcr638","article-title":"The thyroid, iodine and breast cancer","volume":"5","author":"Smyth","year":"2003","journal-title":"Breast Cancer Res."},{"key":"key\n\t\t\t\t2019041104110902300_b12-0670s20","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. v.2.2009. www.nccn.org\/professionals\/physician_gls\/PDF\/prostate.pdf (accessed 2009 Dec 5)."},{"key":"key\n\t\t\t\t2019041104110902300_b13-0670s20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA."},{"issue":"(Suppl 3)","key":"key\n\t\t\t\t2019041104110902300_b14-0670s20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","article-title":"NCCN task force report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J Natl Compr Canc Netw."},{"key":"key\n\t\t\t\t2019041104110902300_b15-0670s20","unstructured":"World Health Organization. FRAX WHO fracture risk assessment tool. www.shef.ac.uk\/FRAX\/ (accessed 2009 Dec 2)."},{"key":"key\n\t\t\t\t2019041104110902300_b16-0670s20","first-page":"1483","article-title":"Osteoporosis and other metabolic bone diseases","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"O\u2019Connell","year":"2008","edition":"7th ed."},{"key":"key\n\t\t\t\t2019041104110902300_b17-0670s20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b18-0670s20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104110902300_b19-0670s20","doi-asserted-by":"crossref","unstructured":"Van Poznak C Hannon R Clack G . Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate Risedronate (SABRE). Presented at 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX; 2008 December 11(abstract 1137). www.abstracts2view.com\/sabcs\/view.php?nu=SABCS08L_817 (accessed 2009 Dec 6).","DOI":"10.1158\/0008-5472.SABCS-1137"},{"key":"key\n\t\t\t\t2019041104110902300_b20-0670s20","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res."},{"key":"key\n\t\t\t\t2019041104110902300_b21-0670s20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist."},{"key":"key\n\t\t\t\t2019041104110902300_b22-0670s20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer."},{"key":"key\n\t\t\t\t2019041104110902300_b23-0670s20","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b24-0670s20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b25-0670s20","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.2006.08.7080","article-title":"Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients","volume":"25","author":"Berruti","year":"2007","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b26-0670s20","volume-title":"Fosamax package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b27-0670s20","volume-title":"Boniva tablets package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041104110902300_b28-0670s20","volume-title":"Boniva injection package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b29-0670s20","volume-title":"Actonel package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b30-0670s20","volume-title":"Reclast package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b31-0670s20","volume-title":"Zometa package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b32-0670s20","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ajhp\/57.14.1315","article-title":"Safety and efficacy of antiestrogens for prevention of breast cancer","volume":"57","author":"Reddy","year":"2000","journal-title":"Am J Health-Syst Pharm."},{"key":"key\n\t\t\t\t2019041104110902300_b33-0670s20","doi-asserted-by":"crossref","unstructured":"Howell A Cuzick J Baum M . Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet. 2005; 365:60\u20132[NTL1]. www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf (accessed 2009 Dec 5).","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"key\n\t\t\t\t2019041104110902300_b34-0670s20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104110902300_b35-0670s20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1056\/NEJMe068120","article-title":"Risk-benefit profiles of raloxifene for women","volume":"355","author":"Stefanick","year":"2006","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104110902300_b36-0670s20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.maturitas.2004.05.007","article-title":"Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene","volume":"51","author":"Tsalikis","year":"2005","journal-title":"Maturitas."},{"key":"key\n\t\t\t\t2019041104110902300_b37-0670s20","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. v.1.2010. www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf (accessed 2009 Dec 9)."},{"key":"key\n\t\t\t\t2019041104110902300_b38-0670s20","volume-title":"Forteo package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104110902300_b39-0670s20","volume-title":"Miacalcin nasal spray package insert","year":"2006"},{"key":"key\n\t\t\t\t2019041104110902300_b40-0670s20","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104110902300_b41-0670s20","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol."},{"key":"key\n\t\t\t\t2019041104110902300_b42-0670s20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b43-0670s20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med."},{"key":"key\n\t\t\t\t2019041104110902300_b44-0670s20","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin- releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"key\n\t\t\t\t2019041104110902300_b45-0670s20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol."},{"key":"key\n\t\t\t\t2019041104110902300_b46-0670s20","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.13.5517","article-title":"Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b47-0670s20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2005.04.013","article-title":"MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL","volume":"7","author":"Lynch","year":"2005","journal-title":"Cancer Cell."},{"key":"key\n\t\t\t\t2019041104110902300_b48-0670s20","unstructured":"National Cancer Institute. Monoclonal antibody CAL. www.cancer.gov\/drugdictionary\/?CdrID=38505 (accessed 2009 Dec 5)."},{"issue":"(20 Pt 2)","key":"key\n\t\t\t\t2019041104110902300_b49-0670s20","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","article-title":"Future treatment of bone metastases","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res."},{"key":"key\n\t\t\t\t2019041104110902300_b50-0670s20","unstructured":"Lark MW Stroup GB Dodds RA . Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. http:\/\/cat.inist.fr\/?aModele=afficheN&cpsidt=877328 (accessed 2009 Dec 5)."},{"key":"key\n\t\t\t\t2019041104110902300_b51-0670s20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041104110902300_b52-0670s20","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041104110902300_b53-0670s20","unstructured":"Popat V . Denosumab efficacy: FDA analysis. Presented at FDA Reproductive Health Drugs Advisory Committee meeting, August 13, 2009. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM179781.pdf (accessed 2009 Dec 5)."},{"key":"key\n\t\t\t\t2019041104110902300_b54-0670s20","unstructured":"Rothstein A . Denosumab safety: FDA analysis. Presented at FDA Reproductive Health Drugs Advisory Committee meeting, August 13, 2009. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM179782.pdf (accessed 2009 Dec 5)."},{"key":"key\n\t\t\t\t2019041104110902300_b55-0670s20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003","volume":"9","author":"Hodgson","year":"2003","journal-title":"Endocr Pract."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/7_Supplement_3\/S20\/28343713\/ajhp0s20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T10:29:35Z","timestamp":1558952975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/7_Supplement_3\/S20\/5129516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":55,"journal-issue":{"issue":"7_Supplement_3","published-print":{"date-parts":[[2010,4,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100078","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,4,1]]},"published":{"date-parts":[[2010,4,1]]}}}